{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T17:29:49Z","timestamp":1772040589969,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,27]]},"DOI":"10.7759\/cureus.28467","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T13:58:52Z","timestamp":1661608732000},"source":"Crossref","is-referenced-by-count":6,"title":["An Orally Administered Nonpathogenic Attenuated Vaccine Virus Can Be Used to Control SARS-CoV-2 Infection: A Complementary Plan B to COVID-19 Vaccination"],"prefix":"10.7759","author":[{"given":"Tibor","family":"Bakacs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Sandig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imre","family":"Kovesdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study [In press]","author":"Watson OJ","year":"2022","unstructured":"Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study [In press]. Lancet Infect Dis. 2022, 10.1016\/S1473-3099(22)00320-6","journal-title":"Lancet Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-03619-8","article-title":"Beyond Omicron: what's next for COVID's viral evolution","volume":"600","author":"Callaway E","year":"2021","unstructured":"Callaway E. Beyond Omicron: what's next for COVID's viral evolution. Nature. 2021, 600:204-7. 10.1038\/d41586-021-03619-8","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade0166","article-title":"As Omicron rages on, virus' path remains unpredictable","volume":"377","author":"Kupferschmidt K","year":"2022","unstructured":"Kupferschmidt K. As Omicron rages on, virus' path remains unpredictable. Science. 2022, 377:352-3. 10.1126\/science.ade0166","journal-title":"Science"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4103\/jehp.jehp_792_21","article-title":"COVID-19 vaccine hesitancy and influence of professional medical guidance","volume":"11","author":"Nair G","year":"2022","unstructured":"Nair G, Venkatesan K, Nair A, Firoz IN, Haroon NN. COVID-19 vaccine hesitancy and influence of professional medical guidance. J Educ Health Promot. 2022, 11:112. 10.4103\/jehp.jehp_792_21","journal-title":"J Educ Health Promot"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-022-00112-8","article-title":"Why scientists are racing to develop more COVID antivirals","volume":"601","author":"Kozlov M","year":"2022","unstructured":"Kozlov M. Why scientists are racing to develop more COVID antivirals. Nature. 2022, 601:496. 10.1038\/d41586-022-00112-8","journal-title":"Nature"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2174\/1871526522666220419130403","article-title":"A clinically validated, broadly active, oral viral superinfection therapy could mitigate symptoms in early-stage COVID-19 patients [In press]","author":"Bakacs T","year":"2022","unstructured":"Bakacs T, Sandig V, Slavin S, Gumrukcu S, Hardy WD, Renz W, Kovesdi I. A clinically validated, broadly active, oral viral superinfection therapy could mitigate symptoms in early-stage COVID-19 patients [In press]. Infect Disord Drug Targets. 2022, 10.2174\/1871526522666220419130403","journal-title":"Infect Disord Drug Targets"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/35099560","article-title":"Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3","volume":"413","author":"Alexopoulou L","year":"2001","unstructured":"Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001, 413:732-8. 10.1038\/35099560","journal-title":"Nature"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.22750","article-title":"Sequential combination of a strong interferon inducer viral vector with low doses of nivolumab plus ipilimumab could provide functional cure in chronic hepatitis B virus infections: technical report proposing a new modality","volume":"14","author":"Bakacs T","year":"2022","unstructured":"Bakacs T, Safadi R, Pusk\u00e1s LG, Feh\u00e9r LZ, Kovesdi I. Sequential combination of a strong interferon inducer viral vector with low doses of nivolumab plus ipilimumab could provide functional cure in chronic hepatitis B virus infections: technical report proposing a new modality. Cureus. 2022, 14:e22750. 10.7759\/cureus.22750","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01410-20","article-title":"Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV","volume":"94","author":"Lokugamage KG","year":"2020","unstructured":"Lokugamage KG, Hage A, de Vries M, et al.. Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV. J Virol. 2020, 94:e01410-20. 10.1128\/JVI.01410-20","journal-title":"J Virol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0906193106","article-title":"Evolution in health and medicine Sackler colloquium: the comparative genomics of viral emergence","volume":"107 Suppl 1","author":"Holmes EC","year":"2010","unstructured":"Holmes EC. Evolution in health and medicine Sackler colloquium: the comparative genomics of viral emergence. Proc Natl Acad Sci U S A. 2010, 107 Suppl 1:1742-6. 10.1073\/pnas.0906193106","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s41124-017-0028-x","article-title":"Post-infection viral superinfection technology could treat HBV and HCV patients with unmet needs","volume":"3","author":"Bakacs T","year":"2018","unstructured":"Bakacs T, Safadi R, Kovesdi I. Post-infection viral superinfection technology could treat HBV and HCV patients with unmet needs. Hepatol Med Policy. 2018, 3:2. 10.1186\/s41124-017-0028-x","journal-title":"Hepatol Med Policy"},{"key":"ref12","article-title":"Preliminary report of a controlled trial of MTH-68\/B virus vaccine treatment in acute B and C hepatitis: a phase II study","volume":"18","author":"Csatary LK","year":"1998","unstructured":"Csatary LK, Telegdy L, Gergely P, Bodey B, Bak\u00e1cs T. Preliminary report of a controlled trial of MTH-68\/B virus vaccine treatment in acute B and C hepatitis: a phase II study. Anticancer Res. 1998, 18:1279-82.","journal-title":"Anticancer Res"},{"key":"ref13","article-title":"Successful treatment of decompensated chronic viral hepatitis by bursal disease virus vaccine","volume":"19","author":"Csatary LK","year":"1999","unstructured":"Csatary LK, Schnabel R, Bak\u00e1cs T. Successful treatment of decompensated chronic viral hepatitis by bursal disease virus vaccine. Anticancer Res. 1999, 19:629-33.","journal-title":"Anticancer Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.08.005","article-title":"Examination of the value of treatment of decompensated viral hepatitis patients by intentionally coinfecting them with an apathogenic IBDV and using the lessons learnt to seriously consider treating patients infected with HIV using the apathogenic hepatitis G virus","volume":"23","author":"Bak\u00e1cs T","year":"2004","unstructured":"Bak\u00e1cs T, Mehrishi JN. Examination of the value of treatment of decompensated viral hepatitis patients by intentionally coinfecting them with an apathogenic IBDV and using the lessons learnt to seriously consider treating patients infected with HIV using the apathogenic hepatitis G virus. Vaccine. 2004, 23:3-13. 10.1016\/j.vaccine.2004.08.005","journal-title":"Vaccine"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00516","article-title":"Recognition of double-stranded RNA and regulation of interferon pathway by Toll-like receptor 10","volume":"9","author":"Lee SM","year":"2018","unstructured":"Lee SM, Yip TF, Yan S, Jin DY, Wei HL, Guo RT, Peiris JS. Recognition of double-stranded RNA and regulation of interferon pathway by Toll-like receptor 10. Front Immunol. 2018, 9:516. 10.3389\/fimmu.2018.00516","journal-title":"Front Immunol"},{"key":"ref16","article-title":"A defined-risks approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacture","volume":"106","author":"Lewis AM Jr","year":"2001","unstructured":"Lewis AM Jr, Krause P, Peden K. A defined-risks approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacture. Dev Biol (Basel). 2001, 106:513-35.","journal-title":"Dev Biol (Basel)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.2830","article-title":"Effective multiple oral administration of reverse genetics engineered infectious bursal disease virus in mice in the presence of neutralizing antibodies","volume":"17","author":"Horny\u00e1k \u00c1","year":"2015","unstructured":"Horny\u00e1k \u00c1, Lipinski KS, Bakonyi T, et al.. Effective multiple oral administration of reverse genetics engineered infectious bursal disease virus in mice in the presence of neutralizing antibodies. J Gene Med. 2015, 17:116-31. 10.1002\/jgm.2830","journal-title":"J Gene Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2174\/1871526519666190405140858","article-title":"Therapeutic exploitation of viral interference","volume":"20","author":"Kovesdi I","year":"2020","unstructured":"Kovesdi I, Bakacs T. Therapeutic exploitation of viral interference. Infect Disord Drug Targets. 2020, 20:423-32. 10.2174\/1871526519666190405140858","journal-title":"Infect Disord Drug Targets"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.7326\/M17-0377","article-title":"Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration adverse event reporting system","volume":"166","author":"Bersoff-Matcha SJ","year":"2017","unstructured":"Bersoff-Matcha SJ, Cao K, Jason M, Ajao A, Jones SC, Meyer T, Brinker A. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration adverse event reporting system. Ann Intern Med. 2017, 166:792-8. 10.7326\/M17-0377","journal-title":"Ann Intern Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.887760","article-title":"Human pegivirus type 1: a common human virus that is beneficial in immune-mediated disease?","volume":"13","author":"Stapleton JT","year":"2022","unstructured":"Stapleton JT. Human pegivirus type 1: a common human virus that is beneficial in immune-mediated disease?. Front Immunol. 2022, 13:887760. 10.3389\/fimmu.2022.887760","journal-title":"Front Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.20303","article-title":"Healing of severe herpes zoster ophthalmicus within a few days: an autobiographical case report","volume":"13","author":"Bakacs T","year":"2021","unstructured":"Bakacs T. Healing of severe herpes zoster ophthalmicus within a few days: an autobiographical case report. Cureus. 2021, 13:e20303. 10.7759\/cureus.20303","journal-title":"Cureus"},{"key":"ref22","article-title":"[Live enteroviral vaccines for the emergency nonspecific prevention of mass respiratory diseases during fall-winter epidemics of influenza and acute respiratory diseases]","author":"Chumakov MP","year":"1992","unstructured":"Chumakov MP, Voroshilova MK, Antsupova AS, et al.. [Live enteroviral vaccines for the emergency nonspecific prevention of mass respiratory diseases during fall-winter epidemics of influenza and acute respiratory diseases]. Zh Mikrobiol Epidemiol Immunobiol. 1992, 37-40.","journal-title":"Zh Mikrobiol Epidemiol Immunobiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc4262","article-title":"Can existing live vaccines prevent COVID-19?","volume":"368","author":"Chumakov K","year":"2020","unstructured":"Chumakov K, Benn CS, Aaby P, Kottilil S, Gallo R. Can existing live vaccines prevent COVID-19?. Science. 2020, 368:1187-8. 10.1126\/science.abc4262","journal-title":"Science"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.907341","article-title":"Vaccination with oral polio vaccine reduces COVID-19 incidence","volume":"13","author":"Yagovkina NV","year":"2022","unstructured":"Yagovkina NV, Zheleznov LM, Subbotina KA, et al.. Vaccination with oral polio vaccine reduces COVID-19 incidence. Front Immunol. 2022, 13:907341. 10.3389\/fimmu.2022.907341","journal-title":"Front Immunol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm1208","article-title":"Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness","volume":"376","author":"Obermeyer F","year":"2022","unstructured":"Obermeyer F, Jankowiak M, Barkas N, et al.. Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness. Science. 2022, 376:1327-32. 10.1126\/science.abm1208","journal-title":"Science"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.04993.x","article-title":"The great billion-year war between ribosome- and capsid-encoding organisms (cells and viruses) as the major source of evolutionary novelties","volume":"1178","author":"Forterre P","year":"2009","unstructured":"Forterre P, Prangishvili D. The great billion-year war between ribosome- and capsid-encoding organisms (cells and viruses) as the major source of evolutionary novelties. Ann N Y Acad Sci. 2009, 1178:65-77. 10.1111\/j.1749-6632.2009.04993.x","journal-title":"Ann N Y Acad Sci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-022-01923-5","article-title":"The hunt for drugs for mild COVID: scientists seek to treat those at lower risk [In press]","author":"Sidik SM","year":"2022","unstructured":"Sidik SM. The hunt for drugs for mild COVID: scientists seek to treat those at lower risk [In press]. Nature. 2022, 10.1038\/d41586-022-01923-5","journal-title":"Nature"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.16.21251535","article-title":"Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated individuals","author":"Kissler SM","year":"2021","unstructured":"Kissler SM, Fauver JR, Mack C, et al.. Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated individuals. medRxiv. 2021, 10.1101\/2021.02.16.21251535","journal-title":"medRxiv"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-017-1351-y","article-title":"How to choose the best journal for your case report","volume":"11","author":"Rison RA","year":"2017","unstructured":"Rison RA, Shepphird JK, Kidd MR. How to choose the best journal for your case report. J Med Case Rep. 2017, 11:198. 10.1186\/s13256-017-1351-y","journal-title":"J Med Case Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus MV","year":"2014","unstructured":"Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 2014, 123:2625-35. 10.1182\/blood-2013-11-492231","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/107983-an-orally-administered-nonpathogenic-attenuated-vaccine-virus-can-be-used-to-control-sars-cov-2-infection-a-complementary-plan-b-to-covid-19-vaccination","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:48:57Z","timestamp":1707508137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/107983-an-orally-administered-nonpathogenic-attenuated-vaccine-virus-can-be-used-to-control-sars-cov-2-infection-a-complementary-plan-b-to-covid-19-vaccination"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,27]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.28467","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,27]]}}}